A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

HIV-1-infection Clinical Trial

— Opti-DOR  

Official title:

Opti-DOR: A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05924438
• Other study ID #: EZ-JW-033
• Secondary ID: DOH-27-052023-52
• Status: Recruiting
• Phase: Phase 3
• Start date: November 8, 2023
• Est. completion date: June 30, 2026

Study information

• Verified date: November 2023
• Source: University of Witwatersrand, South Africa
• Contact: Nompilo Mncwabe, Regulatory Compliance Officer
• Phone: 0110844872
• Email: nmncwabe[@]ezintsha.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, randomised, phase 3, two-arm study conducted over 96 weeks.

The study includes a screening period day - 60 to -1, enrolment visit day 0, and a 96-week treatment follow-up period.

Approximately 600 male and female participants infected with HIV-1 eligible for first-line therapy, will be randomly assigned in a 1:1 ratio approximately 300 participants per treatment group to either Treatment Group 1 DOR/3TC/TDF or Treatment Group 2 DTG/TAF/FTC. All medications will be administered in an open label design.

Description:

One of the major concerns, voiced by researchers, clinicians, and participants, is that data is severely limited to inform participants with side effects, or those wanting to avoid these side effects, as to evidence-based alternatives. As a result, there are no evidence-based regimens available for participants who have begun experiencing weight gain as a side effect on treatment or wanting to avoid weight gain on initiation of antiretrovirals which is now an almost routine side effect for women or Black participants.

Switching to efavirenz-based regimens, while plausibly associated with weight mitigation in efavirenz slow-metabolizers, is accompanied by unacceptable metabolic, organ and neuropsychiatric side effects in the slow metabolizers likely to experience weight loss. There is minimal data on weight changes for switches from integrase inhibitors and having evidence-based options would dramatically add to treatment possibilities for participants. There is some evidence that the use of TDF and doravirine may mitigate the weight gain seen with TAF/integrase inhibitors combinations.

Doravirine is a compelling replacement for the integrase inhibitors similarly well tolerated, and with a high resistance barrier and better lipid profile as compared to other drugs in the non-nucleoside reverse-transcriptase inhibitor class14. In a recent network meta-analysis, DOR/3TC/TDF was found to exhibit superiority in virological suppression to traditional first line non-DTG containing regimes with more tolerable side effects, and a decrease in severe adverse events.

The DOR/3TC/TDF combination would be a major step forward for current treatment guidelines if found to be equivalent in terms of virological suppression and showed a meaningful difference in weight gain, as well as in cardiometabolic outcomes. This potentially offers clinicians and high risk participants an evidence-based alternative to TAF/integrase inhibitor combinations.

We propose a head-to-head, non-inferiority, randomized study with DTG/TAF/FTC, against a formulation of DOR/3TC/TDF, in antiretroviral-naïve overweight participants, with differences in viral suppression as the primary end points weight gain and metabolic changes-being secondary endpoints of interest at 48 Weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

Each participant must meet all the following criteria to be enrolled in this study.

• =18 years old, male or female.

• Documented laboratory diagnosis of infection with HIV-1 (positive enzyme-linked immunosorbent assay HIV-1 antibody test) at screening, with no baseline DOR resistance (please see Table 2 below).

• Is ART naïve.

• BMI= 25 kg/cm2.

• VL >500 copies/ml.

• Must sign an ICF indicating that he or she understands the purpose of, and procedures required for the study and is willing to participate in the study.

• Female participants of childbearing potential (WOCBP) are eligible to participate if willing to use highly effective contraception methods from enrolment, for the duration of the study.

Exclusion criteria:

Participants meeting any of the following criteria will be excluded from the study:

• Is currently participating in any other interventional study or participated in a study with an investigational drug within 60 days of screening.

• Is pregnant, breastfeeding or intends to become pregnant or breastfeed during the study.

• Has active TB co-infection and requires anti-TB treatment.

• Has unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); Child-Pugh C.

• Has pre-existing physical or mental condition (including substance abuse disorder and suicide risk) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.

• Clinically unstable in the investigator's opinion (any pre-existing medical or laboratory abnormalities must be deemed to be stable by the investigator prior to study enrolment).

• Has estimated creatinine clearance <60mL/min per Cockcroft-Gault formula.

• Is taking, and is unable to discontinue, any of the following prohibited medications:

carbamazepine, oxcarbazepine, phenobarbital, phenytoin; the antimycobacterial rifampicin, rifapentine; St. John's Wort (Hypericum perforatum); mitotane; enzalutamide; lumacaftor.

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Drug:
• Delstrigo
Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
• KOCITAF
Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.

Locations

Country	Name	City	State
South Africa	Ezintsha Research Centre	Johannesburg	Gauteng

Sponsors (3)

Lead Sponsor	Collaborator
Professor Francois Venter	Africa Health Research Institute, Merck Sharp & Dohme LLC

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To evaluate the pharmacokinetics of DOR in pregnant women	The observed concentration at 24 hours after dose administration	96 Weeks
Other	Number of pregnant women with treatment related adverse events as assessed by (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.1	Grade 4 AEs which are potentially life-threatening events.	96 Weeks
Other	To describe Patient-Reported Outcomes (PROs) for participants who received DOR/3TC/TDF compared with DTG/TAF/FTC overtime	Change in quality of life (QoL) using, defined as the difference in the summary scores obtained from each individual question (higher scores better outcome)	96 Weeks
Other	To describe Patient-Reported Outcomes (PROs) for participants who received DOR/3TC/TDF compared with DTG/TAF/FTC overtime	Sleep measurement using the sleep assessment questionnaire the participant answers on a scale of 1 - 10, a score >4 indicates a higher likelihood of insomnia	96 Weeks
Other	To describe Patient-Reported Outcomes (PROs) for participants who received DOR/3TC/TDF compared with DTG/TAF/FTC overtime	Food Intake Diary there is no min or max values assessments will be done based upon participant diet	96 Weeks
Other	To describe Patient-Reported Outcomes (PROs) for participants who received DOR/3TC/TDF compared with DTG/TAF/FTC overtime	Mental health questionnaire with higher scores means more risk of mental distress, grand total more than 7 requires referrals for mental health assessment by investigator.	96 Weeks
Primary	The antiretroviral activity of DOR/3TC/TDF compared to DTG/TAF/FTC in the first line treatment, as assessed by the percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48	HIV1-RNA	48 Weeks
Secondary	The antiretroviral activity of DOR/3TC/TDF compared to DTG/TAF/FTC, as assessed by the percentage of participants with HIV-1 RNA < 50 copies/mL at Week 96	HIV-1 RNA	96 Weeks
Secondary	The antiretroviral activity of DOR/3TC/TDF compared with DTG/TAF/FTC, as assessed by the percentage of participants with HIV-1 RNA <200 copies/mL at Week 48 and Week 96	HIV-1 RNA	48 and 96 Weeks
Secondary	Time to virologic failure (defined as confirmed HIV-1 RNA levels = 1000 copies/mL at week 24 or = 200 copies/mL after week 24)	HIV-1 RNA	24 Weeks
Secondary	The immunologic effect of DOR/3TC/TDF compared with DTG/TAF/FTC, as assessed by the mean change from baseline in CD4+ T-cell count at Week 48 and Week 96	CD4-T-cell count	48 and 96 Weeks
Secondary	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Adverse events	96 Weeks
Secondary	The effect of DOR/3TC/TDF compared with DTG/TAF/FTC on weight, as assessed by the mean change from baseline to Week 48 and Week 96	Weight	48 and 96 Weeks
Secondary	The effect on body composition of DOR/3TC/TDF compared with DTG/TAF/FTC, as assessed by the mean change from baseline to Week 48 and Week 96.	Dual-energy X-ray absorptiometry (DXA) scan	48 and 96 Weeks
Secondary	The effect on hematology of DOR/3TC/TDF compared with DTG/TAF/FTC, as assessed by the mean change from baseline to Week 48 and Week 96.	Full blood count	48 and 96 Weeks
Secondary	The effect on lipid profile of DOR/3TC/TDF compared with DTG/TAF/FTC, as assessed by the mean change from baseline to Week 48 and Week 96	fasting lipogram	48 and 96 Weeks
Secondary	To evaluate the pharmacokinetics of DOR in pregnant women	Peak Plasma Concentration (Cmax)	96 Weeks
Secondary	To evaluate the pharmacokinetics of DOR in pregnant women	Area under the plasma concentration versus time curve (AUC)	96 Weeks